(Excerpt republished from the UNC Health Care and UNC School of Medicine Newsroom)

Lisa Carey, MD
Lisa Carey, MD

Komen Scientific Advisory Board Member Lisa Carey, MD, will receive $400,000 to study how HER2+ tumors respond to HER2-targeted therapies. This project will integrate and analyze data from more than 1,300 women participating in six neoadjuvant, first step treatment, clinical trials of HER2- targeted therapies to learn how therapy for HER+ breast cancer patients can be improved. Cary, a member of the UNC Lineberger Comprehensive Cancer Center, is the The Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research, division chief of hematology/oncology, and associate director for clinical sciences at UNC Chapel Hill.

The full article can be found here.